Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma

Intern Med. 2022 Feb 1;61(3):401-405. doi: 10.2169/internalmedicine.6385-20. Epub 2021 Aug 13.

Abstract

A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remarkable antitumor effects; only a single nodule remained in the right upper lobe. The nodule was diagnosed as adenocarcinoma through a biopsy. We subsequently performed right upper lobectomy for multiple primary lung cancer (MPLC). The surgical specimen contained EGFR exon 19 deletion mutations and not exon 20 insertion mutations.

Keywords: EGFR-mutated lung adenocarcinoma; exon 20 insertion; multiple primary lung cancer; pembrolizumab.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / surgery
  • Aged
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Immune Checkpoint Inhibitors
  • Lung
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / surgery
  • Mutation

Substances

  • Immune Checkpoint Inhibitors
  • EGFR protein, human
  • ErbB Receptors